# BPC-157 TB-500: The Wolverine Peptide Blend, Read From the Literature
> BPC-157 TB-500 is the "Wolverine" tissue-repair blend pairing a 15-amino-acid pentadecapeptide with the Ac-LKKTETQ fragment of Thymosin Beta-4. Two mechanisms, one rationale, no controlled combination study — a sourced digest.
A cold reading of the published record: BPC-157's angiogenic-cytoprotective signal and TB-500's actin-sequestration signal, each characterized in animal models, with the FDA 503A and access status surfaced up front.
## What the BPC-157 TB-500 blend is
BPC-157 TB-500 is a research-community name for a two-peptide pairing — BPC-157, a 15-amino-acid pentadecapeptide, plus TB-500, the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4. The "Wolverine" label markets the pair as a single tissue-repair stack, but it is not a single chemical entity and not an approved product. Each constituent carries its own structure, its own proposed mechanism, and its own body of evidence.
BPC-157 has a defined sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, ~1419 Da) and derives from a stable fragment of a protein found in human gastric juice. TB-500 is a shorter heptapeptide (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, ~889 Da) corresponding to residues 17-23 — the actin-binding motif — of the 43-residue intracellular protein Thymosin Beta-4 [3]. The two are co-formulated; the blend itself has no single molecular weight, no CAS number, and no validated composition.
The pairing rests on a clean idea: combine two repair signals that act through largely separate routes. BPC-157 supplies a local cytoprotective and pro-angiogenic signal; TB-500 / Thymosin Beta-4 supplies an intracellular actin-sequestration signal that drives cell migration [4]. Whether the two do more together than each does alone is the central open question — and it is open. No controlled study has tested the combination.
## The Wolverine peptide stack: BPC-157 and TB-500 combined
The term wolverine peptide stack is the marketed form of [the two-mechanism repair rationale](/research#mechanisms). BPC-157 is reported to up-regulate VEGFR2 and activate the VEGFR2-Akt-eNOS pathway, increasing vessel density and accelerating blood-flow recovery in ischemic tissue [2]. TB-500's parent protein, Thymosin Beta-4, binds monomeric G-actin 1:1 and regulates the cytoskeletal dynamics that move cells into a wound [3], [4].
The two signals are described as complementary but largely non-overlapping. That is the entire case for the stack: an angiogenic-cytoprotective leg and a cell-migration leg converging on the same repair process. It is a reasonable hypothesis built from each peptide's independently characterized mechanism. It is not a finding. The single most important fact about this blend is the absence at its center — there is no peer-reviewed combination study defining a synergy ratio, dose, or endpoint for the two given together.
The flagship per-component data sit on the recovery side. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1]. Thymosin Beta-4 enhanced healing of medial collateral ligament injury in rats [8]. Both are animal-model results, and both belong to one constituent at a time. The full case lives in [the research on the Wolverine blend](/research).
## What Is the BPC-157 TB-500 Stack?
### What Is the BPC-157 TB-500 Stack?
The BPC-157 TB-500 stack is the co-formulated pairing of two distinct synthetic peptides marketed as one tissue-repair product. BPC-157 is the angiogenic-cytoprotective leg; TB-500 (the Ac-LKKTETQ fragment of Thymosin Beta-4) is the actin-binding cell-migration leg. The "stack" framing implies a validated combined protocol, but no controlled combination study exists [10]; the published evidence is per-component and overwhelmingly preclinical.
### What Is the Wolverine Peptide Blend?
Wolverine is a research-community name for a two-peptide pairing of BPC-157 (a 15-amino-acid pentadecapeptide) and TB-500 (the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4). It is not a single chemical entity or an approved product — it is a commercial construct that bundles two separately studied compounds under one label [9].
### What Is BPC-157 and TB-500?
BPC-157 is a synthetic stable fragment of a human gastric-juice protein, studied as a cytoprotective and angiogenic signal; TB-500 is the synthetic actin-binding heptapeptide (residues 17-23) of Thymosin Beta-4. The blend co-formulates the two. Most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer [4].
## Why the two peptides are paired
### Why Are BPC-157 and TB-500 Combined?
The rationale pairs BPC-157's angiogenic and cytoprotective signal (VEGFR2-Akt-eNOS) [2] with TB-500's cytoskeletal actin-sequestration signal as complementary, largely non-overlapping mechanisms [3], [4]. The "synergy" is a theoretical extrapolation from each peptide's characterized pathway, not a result from a controlled combination study.
### What Is the BPC-157 and TB-500 Blend Used For in Research?
In animal-model research the two peptides are studied separately for tissue repair: BPC-157 in tendon, ligament, muscle, and wound models [1], [5], [6], and TB-500 / Thymosin Beta-4 in actin-driven cell migration, wound, and angiogenesis models [4], [7]. The blend itself has no controlled-study indication. The most recent BPC-157 systematic review (2025) included 36 studies, only one in humans, and makes no mention of TB-500 or combination use [10].
The per-component evidence is strongest for recovery, which is where [BPC-157 and TB-500 benefits for recovery](/tendon-recovery) are documented in detail.
---
Two repair signals tracked as two bands of cold light — BPC-157's green leg and TB-500's violet leg, each read against its own studies, the convergence left labeled theoretical and the FDA 503A status read first; no clinic behind the aurora and nothing here dispensed.